Mycosis Fungoides and Variants of Mycosis Fungoides: A Retrospective Study of 93 Patients in a Chinese Population at a Single Center.
Cutaneous
Lymphoma
Mycosis fungoides
Retrospective studies
T-Cell
Journal
Annals of dermatology
ISSN: 2005-3894
Titre abrégé: Ann Dermatol
Pays: Korea (South)
ID NLM: 8916577
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
06
08
2019
revised:
10
10
2019
accepted:
14
10
2019
entrez:
29
4
2021
pubmed:
1
2
2020
medline:
1
2
2020
Statut:
ppublish
Résumé
Mycosis fungoides (MF) is the most common types of cutaneous T cell lymphoma. It typically presents with erythematous patches and plaques in the early stage and tumors and extracutaneous involvement with possibly fatal outcomes in the late stage. To facilitate early and accurate diagnosis of MF, it is essential to be knowledgeable of classic and variants of this disease. However, there is limited published data in the Chinese population. To characterize our patient group and to provide additional insight into these malignancies. Patients diagnosed with mycosis fungoides and its variants from October 2012 to January 2018 were retrospectively analyzed. Disease-specific survival (DSS) rate and curve according to early and advanced stages were also calculated. The mean age at diagnosis of ninety-three MF patients was 38.9±1.73 years (range: 6~77). Forty-five males (48.4%) and 48 females (51.6 %) were included in this study. The DSS rate of early-stage MF was 98.6%, while that of advanced stage MF was 88.9%. There was a significant difference in DSS rate between early stage and advanced stage MF ( Early-stage MF has a better prognosis than advanced stage and hMF affects younger people than classic MF among Chinese. This study provides an insight into mycosis fungoides and its variants in a Chinese population.
Sections du résumé
BACKGROUND
BACKGROUND
Mycosis fungoides (MF) is the most common types of cutaneous T cell lymphoma. It typically presents with erythematous patches and plaques in the early stage and tumors and extracutaneous involvement with possibly fatal outcomes in the late stage. To facilitate early and accurate diagnosis of MF, it is essential to be knowledgeable of classic and variants of this disease. However, there is limited published data in the Chinese population.
OBJECTIVE
OBJECTIVE
To characterize our patient group and to provide additional insight into these malignancies.
METHODS
METHODS
Patients diagnosed with mycosis fungoides and its variants from October 2012 to January 2018 were retrospectively analyzed. Disease-specific survival (DSS) rate and curve according to early and advanced stages were also calculated.
RESULTS
RESULTS
The mean age at diagnosis of ninety-three MF patients was 38.9±1.73 years (range: 6~77). Forty-five males (48.4%) and 48 females (51.6 %) were included in this study. The DSS rate of early-stage MF was 98.6%, while that of advanced stage MF was 88.9%. There was a significant difference in DSS rate between early stage and advanced stage MF (
CONCLUSION
CONCLUSIONS
Early-stage MF has a better prognosis than advanced stage and hMF affects younger people than classic MF among Chinese. This study provides an insight into mycosis fungoides and its variants in a Chinese population.
Identifiants
pubmed: 33911704
doi: 10.5021/ad.2020.32.1.14
pmc: PMC7992633
doi:
Types de publication
Journal Article
Langues
eng
Pagination
14-20Informations de copyright
Copyright © 2020 The Korean Dermatological Association and The Korean Society for Investigative Dermatology.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST: The authors have nothing to disclose.
Références
J Am Acad Dermatol. 2003 Aug;49(2):264-70
pubmed: 12894075
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):e72-e74
pubmed: 30102807
Int J Dermatol. 2018 Mar;57(3):306-312
pubmed: 29318586
Australas J Dermatol. 2006 Nov;47(4):248-52
pubmed: 17034466
Br J Dermatol. 2017 Jul;177(1):223-228
pubmed: 28132406
J Am Acad Dermatol. 2012 Dec;67(6):1200-9
pubmed: 22521781
Arch Dermatol. 2000 Apr;136(4):504-10
pubmed: 10768649
Int J Dermatol. 2019 Apr;58(4):449-455
pubmed: 30294921
Int J Dermatol. 2005 Mar;44(3):215-20
pubmed: 15807729
J Am Acad Dermatol. 2016 Jan;74(1):27-58
pubmed: 26547257
Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(2):37-41
pubmed: 26086166
J Am Acad Dermatol. 2014 Dec;71(6):1117-26
pubmed: 25264240
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):e252-e253
pubmed: 30472744
J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1517-23
pubmed: 25600184
J Eur Acad Dermatol Venereol. 2017 May;31(5):808-814
pubmed: 27515575
Arch Dermatol. 2008 Dec;144(12):1609-17
pubmed: 19075143
Blood. 1998 Nov 15;92(10):3578-81
pubmed: 9808550
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
J Clin Oncol. 2010 Nov 1;28(31):4730-9
pubmed: 20855822
Acta Derm Venereol. 2016 May;96(4):535-9
pubmed: 26560051
Int J Dermatol. 2001 Jan;40(1):37-40
pubmed: 11277951
Chin Med J (Engl). 2014;127(4):645-50
pubmed: 24534216
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
Blood. 2009 May 21;113(21):5064-73
pubmed: 19279331
J Am Acad Dermatol. 2017 Sep;77(3):497-502.e2
pubmed: 28645647
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):108-114
pubmed: 30176169